![Enophthalmos Secondary to Metastatic Breast Cancer](http://s1.studyres.com/store/data/008010716_2-9698b8d3d8371f416ff8a7de66fa4447-300x300.png)
Enophthalmos Secondary to Metastatic Breast Cancer
... contraction of fibroblasts and subsequent posterior retraction and tethering of the globe that causes enophthalmos. It is a paradoxical phenomenon. Henderson writes in his 1980 textbook Orbital Tumors: “...as th ...
... contraction of fibroblasts and subsequent posterior retraction and tethering of the globe that causes enophthalmos. It is a paradoxical phenomenon. Henderson writes in his 1980 textbook Orbital Tumors: “...as th ...
Focal/grid laser has been given in
... laser arm Eyes treated with aflibercept had greater mean improvement in VA at week 52 compared with eyes treated with macular laser (+9.7 to +13.1 letters gained versus -1.3 letters) – DA ...
... laser arm Eyes treated with aflibercept had greater mean improvement in VA at week 52 compared with eyes treated with macular laser (+9.7 to +13.1 letters gained versus -1.3 letters) – DA ...
Clinical Trial Endpoints - OncologyPRO
... Urania Dafni has reported no conflict of interest Ulrich Keilholz has reported to be a member of the Speakers Bureau of BMS, Astra Zeneca, MSD, Merck, GSK, Novartis, Roche, Amgen, Pfizer and has served as consultant for all these companies Morten Mau-Sørensen has reported no conflict of interest Pio ...
... Urania Dafni has reported no conflict of interest Ulrich Keilholz has reported to be a member of the Speakers Bureau of BMS, Astra Zeneca, MSD, Merck, GSK, Novartis, Roche, Amgen, Pfizer and has served as consultant for all these companies Morten Mau-Sørensen has reported no conflict of interest Pio ...
(eg, Phase 3 trials of DRCR.net, RESTORE, RISE & RIDE) However
... laser arm Eyes treated with aflibercept had greater mean improvement in VA at week 52 compared with eyes treated with macular laser (+9.7 to +13.1 letters gained versus -1.3 letters) – DA ...
... laser arm Eyes treated with aflibercept had greater mean improvement in VA at week 52 compared with eyes treated with macular laser (+9.7 to +13.1 letters gained versus -1.3 letters) – DA ...
Alimera Sciences Inc.
... our experience in the retinal community with the launch of Visudyne (verteporfin, Novartis) and wanted to get back to retina,” Mr. Holland told Retina Today. “Our name Alimera derives loosely from ancient Greek with the intended meaning of 'day of truth'. We wanted a name with meaning and one that w ...
... our experience in the retinal community with the launch of Visudyne (verteporfin, Novartis) and wanted to get back to retina,” Mr. Holland told Retina Today. “Our name Alimera derives loosely from ancient Greek with the intended meaning of 'day of truth'. We wanted a name with meaning and one that w ...
neovascular glaucoma - M.M.Joshi Eye Institute
... chamber is typically of normal depth, and may contain blood, the pupil is small and the iris trabeculae show new vessels on their surface. The vitreous is often clouded by red cells precluding view of the fundus, the tension is stony hard, all perception of light is lost. Any attempt at operative re ...
... chamber is typically of normal depth, and may contain blood, the pupil is small and the iris trabeculae show new vessels on their surface. The vitreous is often clouded by red cells precluding view of the fundus, the tension is stony hard, all perception of light is lost. Any attempt at operative re ...
Page 1 of 9 Clinical Policy: aflibercept (Eylea), ranibizumab
... B. Macular Edema Following Retinal Vein Occlusion (must meet all): 1. Diagnosis of macular edema following retinal vein occlusion; 2. Prescribed by or in consultation with an ophthalmologist; 3. Request is for Eylea or Lucentis; 4. Dose does not exceed: a. Eylea: 2 mg (0.05 mL) via intravitreal inje ...
... B. Macular Edema Following Retinal Vein Occlusion (must meet all): 1. Diagnosis of macular edema following retinal vein occlusion; 2. Prescribed by or in consultation with an ophthalmologist; 3. Request is for Eylea or Lucentis; 4. Dose does not exceed: a. Eylea: 2 mg (0.05 mL) via intravitreal inje ...
Safety and Efficacy of Ranibizumab and Bevacizumab for the
... comparing the efficacy and safety of the two drugs. Bevacizumab shares identical pharmacology with ranibizumab although structural differences result in differences in receptor affinity and rates of drug clearance. While estimates of the vitreous half-life of ranibizumab vary, it is shorter than tha ...
... comparing the efficacy and safety of the two drugs. Bevacizumab shares identical pharmacology with ranibizumab although structural differences result in differences in receptor affinity and rates of drug clearance. While estimates of the vitreous half-life of ranibizumab vary, it is shorter than tha ...
UPDATES IN RARE CANCERS - Garvan Institute of Medical Research
... stimulate a host immune response that delivers long-lived tumour destruction. These medicines, which work on differing cancer mechanisms, offering new opportunities for patients. There is excellent evidence to show that participation in clinical trials is associated with better outcomes for people w ...
... stimulate a host immune response that delivers long-lived tumour destruction. These medicines, which work on differing cancer mechanisms, offering new opportunities for patients. There is excellent evidence to show that participation in clinical trials is associated with better outcomes for people w ...
Age related Macular Degeneration
... of metastatic colorectal cancer in combination with chemotherapy Incidentally, ranibizumab (Lucentis) is a chemically modified product of bevacizumab (Avastin) that is affinity-matured to have a higher affinity for VEGF, and it is made by the same laboratory, Genetech, that also produces Avastin ...
... of metastatic colorectal cancer in combination with chemotherapy Incidentally, ranibizumab (Lucentis) is a chemically modified product of bevacizumab (Avastin) that is affinity-matured to have a higher affinity for VEGF, and it is made by the same laboratory, Genetech, that also produces Avastin ...
EYLEA-Consent-modified-9-29-14-HB
... not limited to eye-related adverse events such as retinal detachment, a serious infection (endophthalmitis), swelling within the eye (inflammation), cataract formation (clouding of the lens of the eye), glaucoma (increased pressure in the eye), hypotony (reduced pressure in the eye), damage to the r ...
... not limited to eye-related adverse events such as retinal detachment, a serious infection (endophthalmitis), swelling within the eye (inflammation), cataract formation (clouding of the lens of the eye), glaucoma (increased pressure in the eye), hypotony (reduced pressure in the eye), damage to the r ...
Acute lung injury as a possible adverse drug reaction related... gefitinib CASE STUDY R. Ieki, E. Saitoh, M. Shibuya
... 3 and 4 adverse events were rare, there was a relatively high incidence of dyspnoea, which was considered to be disease related. Preliminary data from a phase-II study with gefitinib showed an 18.7% response rate in 210 patients with NSCLC who had progressed after first- or second-line chemotherapy. ...
... 3 and 4 adverse events were rare, there was a relatively high incidence of dyspnoea, which was considered to be disease related. Preliminary data from a phase-II study with gefitinib showed an 18.7% response rate in 210 patients with NSCLC who had progressed after first- or second-line chemotherapy. ...
Tamoxifen and raloxifene for chemoprevention in familial breast
... Amber with Guidance= To be initiated and titrated to a stable dose in secondary care with follow up prescribing and monitoring by primary care where deemed appropriate. ...
... Amber with Guidance= To be initiated and titrated to a stable dose in secondary care with follow up prescribing and monitoring by primary care where deemed appropriate. ...
Microplasmin Shows Promise for Vitreomacular Traction Treatment
... generally well tolerated, with PVD induction observed in some patients (including five of 10 patients in whom microplasmin was injected 7 days before surgery). Macular hole occurs in about 0.14% of the general ...
... generally well tolerated, with PVD induction observed in some patients (including five of 10 patients in whom microplasmin was injected 7 days before surgery). Macular hole occurs in about 0.14% of the general ...
drug name: anastrozole
... 4. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. EndocrineRelated Cancer 1999;6(1):75-92. 5. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, nonsteroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postm ...
... 4. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. EndocrineRelated Cancer 1999;6(1):75-92. 5. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, nonsteroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postm ...
Cylene Builds on Success, Presents Second CK2 Inhibitor at AACR
... transcription, angiogenesis, Hsp90 chaperone pathway and the DNA damage response. ...
... transcription, angiogenesis, Hsp90 chaperone pathway and the DNA damage response. ...
PDF - Juno Therapeutics
... Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer. Juno is being launched with an initial investment of $120M, making it one of the largest Series A biotech startups in history. Initial in ...
... Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer. Juno is being launched with an initial investment of $120M, making it one of the largest Series A biotech startups in history. Initial in ...
Introduction to Cancer Biomarkers
... • On July 31, 2014, the FDA issued “Guidance for Industry: In Vitro Companion ...
... • On July 31, 2014, the FDA issued “Guidance for Industry: In Vitro Companion ...
To Cholesterol and Beyond: New Uses for Statin Therapy
... colon cancer (Int J Oncol. 2009 Nov;35(5):1037-43; also Int J Cancer. 2010 Feb 15;126(4):852-63) ...
... colon cancer (Int J Oncol. 2009 Nov;35(5):1037-43; also Int J Cancer. 2010 Feb 15;126(4):852-63) ...
NEW OPHTHALMIC MEDICATIONS – Helpful or Harmful? Brian C
... animal’s natural repair system by providing the optimal environment for healing. This information is based on in vitro tests and a single published “preliminary study” in rabbits. In this study, an experimental epithelial wound created in normal rabbits treated with the cross-linked hyaluronan had r ...
... animal’s natural repair system by providing the optimal environment for healing. This information is based on in vitro tests and a single published “preliminary study” in rabbits. In this study, an experimental epithelial wound created in normal rabbits treated with the cross-linked hyaluronan had r ...
Report 1 - Curing Ken
... 1945), based on the claim this will affect the pH of the body generally, so reducing the risk of heart disease and cancer. According to the Canadian Cancer Society, "there is no evidence to support any of these claims." Breuss diet – a diet based on vegetable juice and tea devised by Rudolf Breuss ( ...
... 1945), based on the claim this will affect the pH of the body generally, so reducing the risk of heart disease and cancer. According to the Canadian Cancer Society, "there is no evidence to support any of these claims." Breuss diet – a diet based on vegetable juice and tea devised by Rudolf Breuss ( ...
Clinical trials briefsheet
... improve survival in people with a certain type of breast cancer. • We funded the largest ever trial for people with operable pancreatic cancer. This showed that giving chemotherapy to patients after surgery could extend the lives of people with the disease – this is now standard pract ...
... improve survival in people with a certain type of breast cancer. • We funded the largest ever trial for people with operable pancreatic cancer. This showed that giving chemotherapy to patients after surgery could extend the lives of people with the disease – this is now standard pract ...
High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation
... dose led to statistically significant improvements in visual acuity and macular anatomy within the first 3 months of treatment. However, similar to the present study, their longer-term results failed to demonstrate significant improvement in visual acuity (in press 2013). Therefore, the higher dose ...
... dose led to statistically significant improvements in visual acuity and macular anatomy within the first 3 months of treatment. However, similar to the present study, their longer-term results failed to demonstrate significant improvement in visual acuity (in press 2013). Therefore, the higher dose ...
May 26, 2011 - Eleison Selects CRO Pharm
... outstanding capabilities and unique experience, which will help ensure the successful execution of our planned phase III study of glufosfamide. Furthermore, POI’s agreement to invest up to $2 million in Eleison is affirmation of glufosfamide’s and Eleison’s potential.” John Hovre, Chief Operating Of ...
... outstanding capabilities and unique experience, which will help ensure the successful execution of our planned phase III study of glufosfamide. Furthermore, POI’s agreement to invest up to $2 million in Eleison is affirmation of glufosfamide’s and Eleison’s potential.” John Hovre, Chief Operating Of ...